Actively Recruiting
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Led by Herlev Hospital · Updated on 2023-09-25
205
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
CONDITIONS
Official Title
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy-verified anal cancer
- Eligible for curative intended radiotherapy
- Written and oral consent
You will not qualify if you...
- Other malignant disease within the past 5 years (excluding basal cell carcinoma)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oncology dept, Herlev and Gentofte Hospital
Herlev, Denmark, 2730
Actively Recruiting
Research Team
E
Eva Serup-Hansen, MD, PhD
CONTACT
K
katrine S storm, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here